Qianhui Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qianhui Zheng has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Guanghui Liu
Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
10 shared publications - Guoxin Li
Department of General Surgery, Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
10 shared publications - Hao Liu
Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, China
10 shared publications - Jingsi Liu
Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
10 shared publications - Kaibiao Xu
Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
10 shared publications - Suyue Pan
Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China
10 shared publications
Latest Publications
- Open Access
- 20 September 2026
- Published by Elsevier in SSRN Electronic Journal
TM7SF3 Drives PI3K/AKT-mediated CX3CL1 Secretion to Promote Macrophage M2 Polarization in Gastric Cancer
Background: Gastric cancer (GC) remains one of the leading causes of cancer-related mortality worldwide, macrophage is a contributor to tumor progression and resistance to immunotherapy. Transmembrane 7 superfamily member 3 (TM7SF3) has been implicated in cellular stress responses, but its immune function remain unknown in GC.Methods: TM7SF3 expression and its clinical significance were comprehensively analyzed using different datasets and validated in human GC specimens. Gain- and loss-of-function assays were performed in human and murine GC cell lines to evaluate cell proliferation, migration and apoptosis viability. Macrophage polarization was assessed by using conditioned medium-induced THP-1-derived macrophages, bone marrow-derived macrophages and xenograft models. Patient-derived organoids and xenograft models were used to evaluate the efficacy of anti-PD-1 immunotherapy in combination with Trametinib.Results: TM7SF3 was significantly upregulated in GC tissues and was associated with advanced tumor stage and poor prognosis. Functionally, TM7SF3 promoted GC cell proliferation and migration while suppressing apoptosis. Mechanistically, TM7SF3 activated the downstream PI3K/AKT signaling pathway, resulting in increased CX3CL1 expression and secretion, which subsequently promoted macrophage M2 polarization. Clinically, efficacy of Trametinib was found to depend on TM7SF3 expression level and was exhibited by patient-derived organoids model in vitro. The antitumor activity of anti-PD-1 therapy in combination with Trametinib was further enhanced in TM7SF3-overexpressed GC cells in vivo. Conclusion: TM7SF3 drived macrophage M2 polarization by activating the PI3K/AKT /CX3CL1 signaling axis. Trametinib may de as a TM7SF3-targeted drug improved the efficacy of immune checkpoint blockade, and highlighting TM7SF3 as a promising biomarker and therapeutic target for GC.
- 20 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTM7SF3 Drives PI3K/AKT-mediated CX3CL1 Secretion to Promote Macrophage M2 Polarization in Gastric Cancer
Background: Gastric cancer (GC) remains one of the leading causes of cancer-related mortality worldwide, macrophage is a contributor to tumor progression and resistance to immunotherapy. Transmembrane 7 superfamily member 3 (TM7SF3) has been implicated in cellular stress responses, but its immune function remain unknown in GC.Methods: TM7SF3 expression and its clinical significance were comprehensively analyzed using different datasets and validated in human GC specimens. Gain- and loss-of-function assays were performed in human and murine GC cell lines to evaluate cell proliferation, migration and apoptosis viability. Macrophage polarization was assessed by using conditioned medium-induced THP-1-derived macrophages, bone marrow-derived macrophages and xenograft models. Patient-derived organoids and xenograft models were used to evaluate the efficacy of anti-PD-1 immunotherapy in combination with Trametinib.Results: TM7SF3 was significantly upregulated in GC tissues and was associated with advanced tumor stage and poor prognosis. Functionally, TM7SF3 promoted GC cell proliferation and migration while suppressing apoptosis. Mechanistically, TM7SF3 activated the downstream PI3K/AKT signaling pathway, resulting in increased CX3CL1 expression and secretion, which subsequently promoted macrophage M2 polarization. Clinically, efficacy of Trametinib was found to depend on TM7SF3 expression level and was exhibited by patient-derived organoids model in vitro. The antitumor activity of anti-PD-1 therapy in combination with Trametinib was further enhanced in TM7SF3-overexpressed GC cells in vivo. Conclusion: TM7SF3 drived macrophage M2 polarization by activating the PI3K/AKT /CX3CL1 signaling axis. Trametinib may de as a TM7SF3-targeted drug improved the efficacy of immune checkpoint blockade, and highlighting TM7SF3 as a promising biomarker and therapeutic target for GC.
- Open Access
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Gene Ontology enrichment analysis of differentially expressed genes in TBA-positive vs. TBA-negative gastric cancer cells.
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Gene Ontology enrichment analysis of differentially expressed genes in TBA-positive vs. TBA-negative gastric cancer cells.
- Open Access
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Kaplan–Meier survival curves for OS in TBA-positive and TBA-negative patients with gastric cancer.
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Kaplan–Meier survival curves for OS in TBA-positive and TBA-negative patients with gastric cancer.
- Open Access
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Neuronal autoantibody staining patterns and identification of known PNS-related antibodies in patients with gastric cancer. Ab, antibody.
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Neuronal autoantibody staining patterns and identification of known PNS-related antibodies in patients with gastric cancer. Ab, antibody.
- Open Access
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Reduced CD8+ T-cell infiltration and altered CD4+/CD8+ ratio in TBA-positive gastric cancer tissues. ns, not significant.
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Reduced CD8+ T-cell infiltration and altered CD4+/CD8+ ratio in TBA-positive gastric cancer tissues. ns, not significant.
- Open Access
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Neuronal autoantibodies have been identified in immune-mediated encephalitis, most of which are related to paraneoplastic neurologic syndromes (PNS). We detected neuronal autoantibodies in patients with gastric cancer without PNS and illustrated their correlation with clinical prognosis. All serum samples were tested by the mouse brain tissue-based assay (TBA) using immunofluorescence for screening neuronal autoantibodies. Known PNS-related neuronal autoantibodies were detected by cell-based assay. A single-center cohort has been started in Nanfang Hospital. The T-cell status of the tumor microenvironment was assessed. Single-cell sequencing was performed with limited tumor samples. Patients were grouped into TBA-positive (n = 144) and TBA-negative (n = 179) groups by the TBA status. Further screening of TBA+ specimens using the cell-based assay method revealed known PNS-related autoantibodies in 13.2% (19/144) of cases. Additionally, TBA-positive patients with gastric cancer exhibited lower CD8+ T-cell infiltration in the tumor tissue. The survival analysis show that neuronal autoantibodies in patients (TBA-positive) were associated with shorter overall survival (OS; P = 0.014). In the multivariate survival analysis, TBA positivity was still associated with shortened OS after adjusting the major covariates (HR = 2.28; 95% confidence interval, 1.31–3.97; P = 0.004). Meanwhile, single-cell sequencing indicates that cell junction assembly and synapse organization may play important roles in biological process. In this cohort study, neuronal autoantibodies were highly prevalent among patients with gastric cancer and were associated with shortened OS and features of immunosuppression within the tumor microenvironment, suggesting a candidate for exploring therapeutic relevance, with further mechanistic studies needed for validation.Significance:Neuronal autoantibodies are prevalent in patients with gastric cancer, and patients without neurologic symptoms are linked to shorter survival and immunosuppression. These results provide a new direction for prognostic biomarkers and targeted therapy exploration.
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Neuronal autoantibodies have been identified in immune-mediated encephalitis, most of which are related to paraneoplastic neurologic syndromes (PNS). We detected neuronal autoantibodies in patients with gastric cancer without PNS and illustrated their correlation with clinical prognosis. All serum samples were tested by the mouse brain tissue-based assay (TBA) using immunofluorescence for screening neuronal autoantibodies. Known PNS-related neuronal autoantibodies were detected by cell-based assay. A single-center cohort has been started in Nanfang Hospital. The T-cell status of the tumor microenvironment was assessed. Single-cell sequencing was performed with limited tumor samples. Patients were grouped into TBA-positive (n = 144) and TBA-negative (n = 179) groups by the TBA status. Further screening of TBA+ specimens using the cell-based assay method revealed known PNS-related autoantibodies in 13.2% (19/144) of cases. Additionally, TBA-positive patients with gastric cancer exhibited lower CD8+ T-cell infiltration in the tumor tissue. The survival analysis show that neuronal autoantibodies in patients (TBA-positive) were associated with shorter overall survival (OS; P = 0.014). In the multivariate survival analysis, TBA positivity was still associated with shortened OS after adjusting the major covariates (HR = 2.28; 95% confidence interval, 1.31–3.97; P = 0.004). Meanwhile, single-cell sequencing indicates that cell junction assembly and synapse organization may play important roles in biological process. In this cohort study, neuronal autoantibodies were highly prevalent among patients with gastric cancer and were associated with shortened OS and features of immunosuppression within the tumor microenvironment, suggesting a candidate for exploring therapeutic relevance, with further mechanistic studies needed for validation.Significance:Neuronal autoantibodies are prevalent in patients with gastric cancer, and patients without neurologic symptoms are linked to shorter survival and immunosuppression. These results provide a new direction for prognostic biomarkers and targeted therapy exploration.
- Open Access
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Cox proportional hazards regression analysis of factors affecting OS in patients with gastric cancer.
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Cox proportional hazards regression analysis of factors affecting OS in patients with gastric cancer.
- Open Access
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Comparison of 3-year OS among TBA-negative, CBA-positive, and TBA-positive CBA-negative groups.
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Comparison of 3-year OS among TBA-negative, CBA-positive, and TBA-positive CBA-negative groups.
- Open Access
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Baseline characteristics of patients with gastric cancer by TBA status.
- 3 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer
Baseline characteristics of patients with gastric cancer by TBA status.